TY - JOUR
T1 - Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma
AU - Karimipour, Darius J.
AU - Schwartz, Jennifer L.
AU - Wang, Timothy S.
AU - Bichakjian, Christopher K.
AU - Orringer, Jeffrey S.
AU - King, Anya L.
AU - Huang, Conway C.
AU - Johnson, Timothy M.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2005/5
Y1 - 2005/5
N2 - Background: A significant portion of cutaneous melanoma may remain after subtotal incisional biopsy. The accuracy of microstaging and impact on clinical practice in this scenario are unknown. Objective: Our purpose was to examine microstaging accuracy of an initial incisional biopsy with a significant portion of the clinical lesion remaining (≥50%). Methods: Patients with cutaneous melanoma, diagnosed by incisional biopsy with ≥50% of the lesion remaining, were prospectively evaluated for microstaging accuracy, comparing initial Breslow depth (BD1) to final depth (BD2) after excision of the residual lesion. Impact on prognosis and treatment was also evaluated. Results: Two hundred fifty of 1783 patients (14%) presented with ≥50% residual clinical lesion after incisional biopsy. The mean BD1 was 0.66 mm; the mean BD2, 1.07 mm (P =. 001). After complete excision of the residual lesion, upstaging occurred in 21% and 10% became candidates for sentinel node biopsy. Conclusion: An incisional biopsy with ≥50% clinical lesion remaining afterward may be inadequate for accurate microstaging of melanoma. This scenario is relatively uncommon but clinically significant.
AB - Background: A significant portion of cutaneous melanoma may remain after subtotal incisional biopsy. The accuracy of microstaging and impact on clinical practice in this scenario are unknown. Objective: Our purpose was to examine microstaging accuracy of an initial incisional biopsy with a significant portion of the clinical lesion remaining (≥50%). Methods: Patients with cutaneous melanoma, diagnosed by incisional biopsy with ≥50% of the lesion remaining, were prospectively evaluated for microstaging accuracy, comparing initial Breslow depth (BD1) to final depth (BD2) after excision of the residual lesion. Impact on prognosis and treatment was also evaluated. Results: Two hundred fifty of 1783 patients (14%) presented with ≥50% residual clinical lesion after incisional biopsy. The mean BD1 was 0.66 mm; the mean BD2, 1.07 mm (P =. 001). After complete excision of the residual lesion, upstaging occurred in 21% and 10% became candidates for sentinel node biopsy. Conclusion: An incisional biopsy with ≥50% clinical lesion remaining afterward may be inadequate for accurate microstaging of melanoma. This scenario is relatively uncommon but clinically significant.
UR - http://www.scopus.com/inward/record.url?scp=18144429790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18144429790&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2004.09.031
DO - 10.1016/j.jaad.2004.09.031
M3 - Article
C2 - 15858469
AN - SCOPUS:18144429790
SN - 0190-9622
VL - 52
SP - 798
EP - 802
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 5
ER -